Table 1.
MS-COV-risk score.
Table 2.
Characteristics of the AUT-MuSC-19 cohort.
Fig 1.
COVID-19 outcome according to DMT classes (A) and single substances (B). DMT: disease modifying treatment. IM-DMT: Immunomodulating DMT = dimethyl fumarate, glatiramer acetate, interferon beta preparations, natalizumab, and teriflunomide. IS-DMT: Immunosuppressive DMT = alemtuzumab, cladribine, fingolimod, ocrelizumab or rituximab. p-values calculated by chi-square test. N-DMT: no DMT.
Table 3.
COVID-19 severity and mortality according to a-priori risk and DMT class.
Table 4.
COVID-19 severity and mortality depend on a priori risk but not DMT class.